11:00 AM - 11:40 AM ET Virtual

Behind the scenes at Isomorphic Labs

We’re joined by Isomorphic Labs’ Chief Scientific Officer Miles Congreve and Chief AI Officer Max Jaderberg for an in-depth conversation. What’s next after Isomorphic’s $600 million raise this past winter — and are they finally ready to enter the clinic?

 
Miles Congreve
Miles Congreve
Chief Scientific Officer
Isomorphic Labs

Max Jaderberg
Max Jaderberg
Chief AI Officer
Isomorphic Labs

Andrew Dunn
Andrew DunnModerator
Senior Biopharma Correspondent
Endpoints News
11:45 AM - 12:25 PM ET Virtual

AI’s next moonshots

Over the past few years, AI models have made breakthroughs in biology, like when AlphaFold cracked protein structure, or RFdiffusion took a major step forward on de novo protein design. What big swings could come next? We’ll talk to pioneers on the bleeding edge about building autonomous labs, virtual cells, AI scientists, and more.

 
Michelle Lee
Michelle Lee
Founder & CEO
Medra AI

Sam Rodriques
Sam Rodriques
CEO
FutureHouse

Bo Wang
Bo Wang
SVP & Head of Biomedical AI
Xaira Therapeutics

Vivek Natarajan
Vivek Natarajan
Research Scientist
Google DeepMind

Andrew Dunn
Andrew DunnModerator
Senior Biopharma Correspondent
Endpoints News
12:30 PM - 1:10 PM ET Virtual

How the world's largest drugmakers are betting on AI’s future

AI experts are full of big ideas for new tech and new tools, but it takes investment to make those ideas a reality. We'll sit down with leaders of some of the world's largest drugmakers who are deciding which ideas move from the notebook to the real world, and which aren't ready for primetime. Hear how the biopharma industry's largest companies are betting on AI in 2025 and beyond.

 
Aliza Apple
Aliza Apple
VP, Catalyze360 AI/ML
Eli Lilly and Company

Sally John
Sally John
SVP, Informatics and Predictive Sciences
Bristol Myers Squibb

Madhavi Ramakrishna
Madhavi Ramakrishna
SVP of Enterprise AI
GSK

Sara Mostafavi
Sara Mostafavi
VP of AI Biology & Translation
Genentech

Andrew Dunn
Andrew DunnModerator
Senior Biopharma Correspondent
Endpoints News
1:15 PM - 1:45 PM ET Virtual

Navigating AI adoption in pharma manufacturing: Change management, mindset shifts, and GMP industrialization

Adoption rates of AI in Pharma Manufacturing vary significantly, creating a two-speed landscape: industry leaders who have invested for years and are reaping transformative benefits, and others scrambling to catch up to remain relevant. Hear from industry experts Damiano Dragone and Toni Manzano about the critical role of change management and mindset shifts in enabling big and medium-sized corporations to successfully adopt AI, as well as strategies for overcoming resistance, fostering AI-ready cultures, and the pivotal role of GMP industrialization in scaling AI solutions.

 
sponsored by
AIZON
Damiano Dragone
Damiano Dragone
AI Champion, External Supply Operations Quality
Pfizer

Toni Manzano
Toni Manzano
Co-Founder & Chief Science Officer
Aizon

Surani Fernando
Surani FernandoModerator
Healthcare Journalist, Writer & Podcast Producer
Raising Biotech Podcast
4:00 PM - 8:00 PM ET In-Person

AI in biopharma: New York City happy hour

4:15 PM - 4:45 PM ET In-Person

How AI can tackle cancer — with Siddhartha Mukherjee

Earlier this year, Pulitzer-winning physician-author Siddhartha Mukherjee joined forces with LinkedIn co-founder Reid Hoffman to launch Manas AI. How does his long and varied career across researching, writing, and building biotechs shape his thinking on AI's role in medicine and drug discovery? Hear from one of science's most influential and prolific voices on the current powers and future potential of this new technology.

 
Siddhartha Mukherjee
Siddhartha Mukherjee
CEO
Manas AI

Andrew Dunn
Andrew DunnModerator
Senior Biopharma Correspondent
Endpoints News
4:45 PM - 5:30 PM ET In-Person

The ethics of AI in science and healthcare

Silicon Valley is about moving fast, while the world of medicine starts with first, doing no harm. How does that tension play out with AI's growing role in everything from lab research to clinical trials to medical care? We'll talk through the biggest ethical questions for the field, strategies to build responsible AI, and whether the societal challenges will ultimately be bigger than the technological.  

 
Inmaculada de Melo-Martín
Inmaculada de Melo-Martín
Professor of Medical Ethics
Weill Cornell Medicine

Elliott Green
Elliott Green
CEO
Dandelion Health

Chris Fussell
Chris Fussell
Co-founder & President, Operations
Lila Sciences

Vardit Ravitsky
Vardit Ravitsky
President & CEO
The Hastings Center for Bioethics

Andrew Dunn
Andrew DunnModerator
Senior Biopharma Correspondent
Endpoints News
5:30 PM - 6:00 PM ET In-Person

In conversation with David Reese

Amgen Chief Techonology Officer David Reese sits down with Andrew Dunn to talk AI at Amgen.

 
David Reese
David Reese
EVP & Chief Technology Officer
Amgen

Andrew Dunn
Andrew DunnModerator
Senior Biopharma Correspondent
Endpoints News